First triple REXUS campaign - Flying systems twice on one rocket campaign

For the first time in 12 years of REXUS (Rocket Experiments for University Students) history, an on-range reconditioning of flown systems was performed. The Mobile Rocket Base (MORABA) has accomplished an on-range check to reuse two already flown modules during the same campaign. The trigger was the REXUS 24 non-nominal flight. Because of this issue, REXUS 23 was on hold and finally was accepted for launch during the REXUS 23/ 25/ 26 triple campaign. The campaign was executed with just two service and two recovery systems for three rockets. This means a reuse of systems on the same campaign was crucial for a successful threelaunch campaign. Using a new procedure for checking the system condition, DLR MORABA could reduce the costs without affecting the quality of the additional flight, provided the flown systems were in proper shape after their first flight. The aim of this paper is to illustrate the campaign procedure as well as the procedure of on-range checking for the service and recovery module

Zusammenarbeit mit klinischen Auftragsforschungsinstituten

Clinical trials with pharmaceuticals or medical devices make complex demands on sponsors and participating centers. During the past two decades, sponsors have increasingly delegated regulatory and organizational tasks to clinical research organizations (CRO). As a rule, these companies are the main interface for the collaboration with the participating study centers. The main purpose of the participation is the support of the study centers for achieving an optimal study quality. The study centers involved in the DOG working group on clinical study centers perceived varying experiences in the collaboration with CROs. In the future these experiences will be systematically assessed at the participating study centers and analyzed by the coordinating investigator. Reflecting these experiences to the respective CROs and the delegating sponsors will contribute to the quality of support by CROs and herewith to the quality of clinical trials. This paper presents which areas of collaboration will be assessed and analyzed